ES2761340T3 - Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas - Google Patents
Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas Download PDFInfo
- Publication number
- ES2761340T3 ES2761340T3 ES12829655T ES12829655T ES2761340T3 ES 2761340 T3 ES2761340 T3 ES 2761340T3 ES 12829655 T ES12829655 T ES 12829655T ES 12829655 T ES12829655 T ES 12829655T ES 2761340 T3 ES2761340 T3 ES 2761340T3
- Authority
- ES
- Spain
- Prior art keywords
- formulation
- plga
- atec
- lactide
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495672P | 2011-06-10 | 2011-06-10 | |
| PCT/US2012/041950 WO2013036309A2 (en) | 2011-06-10 | 2012-06-11 | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2761340T3 true ES2761340T3 (es) | 2020-05-19 |
Family
ID=47832748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12829655T Active ES2761340T3 (es) | 2011-06-10 | 2012-06-11 | Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9814773B2 (https=) |
| EP (1) | EP2717914B1 (https=) |
| JP (1) | JP6339011B2 (https=) |
| KR (1) | KR20140060274A (https=) |
| CN (1) | CN103945865B (https=) |
| AU (1) | AU2012304909B2 (https=) |
| BR (1) | BR112013031685B1 (https=) |
| CA (1) | CA2838289C (https=) |
| CY (1) | CY1122771T1 (https=) |
| DK (1) | DK2717914T3 (https=) |
| ES (1) | ES2761340T3 (https=) |
| HR (1) | HRP20192276T1 (https=) |
| HU (1) | HUE047737T2 (https=) |
| IN (1) | IN2013MN02384A (https=) |
| LT (1) | LT2717914T (https=) |
| MX (1) | MX359119B (https=) |
| PL (1) | PL2717914T3 (https=) |
| PT (1) | PT2717914T (https=) |
| RS (1) | RS60051B1 (https=) |
| SI (1) | SI2717914T1 (https=) |
| SM (1) | SMT202000021T1 (https=) |
| WO (1) | WO2013036309A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2902951T3 (es) * | 2013-05-24 | 2022-03-30 | Icon Bioscience Inc | Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas |
| PL3139914T3 (pl) * | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| TWI731853B (zh) * | 2015-03-18 | 2021-07-01 | 日商參天製藥股份有限公司 | 徐放性醫藥組成物及其安定化方法 |
| EP3318280A4 (en) * | 2015-07-01 | 2018-08-22 | Santen Pharmaceutical Co., Ltd | Depot preparation containing citric acid ester |
| US10786515B2 (en) * | 2015-08-03 | 2020-09-29 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| CA2998504C (en) | 2015-09-21 | 2023-06-20 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| WO2018172850A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| KR101957599B1 (ko) | 2017-10-23 | 2019-03-13 | 김상현 | 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지 |
| JP7394770B2 (ja) | 2018-02-09 | 2023-12-08 | アイコン バイオサイエンス，インコーポレイテッド | 注射器から少量の用量を装填および送達するためのシステム、キット、および方法 |
| AU2019263302C1 (en) | 2018-05-01 | 2024-10-31 | Chibi, Inc. | Liquid depot for non-invasive sustained delivery of agents to the eye |
| CN112423740A (zh) | 2018-05-01 | 2021-02-26 | 奇比有限公司 | 用于将药物持续递送至视网膜的滴眼剂制剂和方法 |
| JP2023526512A (ja) * | 2020-05-22 | 2023-06-21 | トラスティーズ オブ ボストン ユニバーシティ | 線維化疾患を処置するための方法および組成物 |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
| CA3227324A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658432B1 (fr) * | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
| WO2002000137A1 (en) * | 2000-06-28 | 2002-01-03 | Shukla Atul J | Biodegradable vehicles and delivery systems of biologically active substances |
| US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| TWI353854B (en) * | 2002-06-25 | 2011-12-11 | Alza Corp | Short duration depot formulations |
| MXPA05013003A (es) * | 2003-05-30 | 2006-03-17 | Alza Corp | Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion. |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| EP2452670A1 (en) * | 2004-10-01 | 2012-05-16 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| BRPI0516308A2 (pt) * | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| WO2010105093A2 (en) * | 2009-03-12 | 2010-09-16 | Delpor, Inc. | Implantable device for long-term delivery of drugs |
| EP2269663B1 (en) * | 2009-07-03 | 2018-03-07 | Armbruster Biotechnology GmbH | Bone graft and biocomposite |
-
2012
- 2012-06-11 HU HUE12829655A patent/HUE047737T2/hu unknown
- 2012-06-11 KR KR1020147000443A patent/KR20140060274A/ko not_active Withdrawn
- 2012-06-11 HR HRP20192276TT patent/HRP20192276T1/hr unknown
- 2012-06-11 PT PT128296555T patent/PT2717914T/pt unknown
- 2012-06-11 CA CA2838289A patent/CA2838289C/en active Active
- 2012-06-11 BR BR112013031685-3A patent/BR112013031685B1/pt active IP Right Grant
- 2012-06-11 SI SI201231706T patent/SI2717914T1/sl unknown
- 2012-06-11 SM SM20200021T patent/SMT202000021T1/it unknown
- 2012-06-11 ES ES12829655T patent/ES2761340T3/es active Active
- 2012-06-11 AU AU2012304909A patent/AU2012304909B2/en active Active
- 2012-06-11 MX MX2013014461A patent/MX359119B/es active IP Right Grant
- 2012-06-11 CN CN201280028816.4A patent/CN103945865B/zh active Active
- 2012-06-11 WO PCT/US2012/041950 patent/WO2013036309A2/en not_active Ceased
- 2012-06-11 JP JP2014514933A patent/JP6339011B2/ja active Active
- 2012-06-11 RS RS20191574A patent/RS60051B1/sr unknown
- 2012-06-11 IN IN2384MUN2013 patent/IN2013MN02384A/en unknown
- 2012-06-11 EP EP12829655.5A patent/EP2717914B1/en active Active
- 2012-06-11 US US14/124,631 patent/US9814773B2/en active Active
- 2012-06-11 PL PL12829655T patent/PL2717914T3/pl unknown
- 2012-06-11 LT LTEP12829655.5T patent/LT2717914T/lt unknown
- 2012-06-11 DK DK12829655.5T patent/DK2717914T3/da active
-
2020
- 2020-01-17 CY CY20201100042T patent/CY1122771T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6339011B2 (ja) | 2018-06-06 |
| WO2013036309A3 (en) | 2013-05-10 |
| US20140140992A1 (en) | 2014-05-22 |
| MX2013014461A (es) | 2014-05-14 |
| EP2717914A4 (en) | 2015-05-13 |
| EP2717914B1 (en) | 2019-10-30 |
| AU2012304909B2 (en) | 2017-06-08 |
| BR112013031685A2 (pt) | 2017-02-07 |
| PT2717914T (pt) | 2019-12-18 |
| KR20140060274A (ko) | 2014-05-19 |
| WO2013036309A2 (en) | 2013-03-14 |
| SMT202000021T1 (it) | 2020-03-13 |
| DK2717914T3 (da) | 2020-01-20 |
| CN103945865B (zh) | 2016-10-26 |
| SI2717914T1 (sl) | 2020-07-31 |
| CY1122771T1 (el) | 2021-05-05 |
| PL2717914T3 (pl) | 2020-05-18 |
| MX359119B (es) | 2018-09-14 |
| AU2012304909A1 (en) | 2013-12-19 |
| IN2013MN02384A (https=) | 2015-06-12 |
| JP2014516087A (ja) | 2014-07-07 |
| EP2717914A2 (en) | 2014-04-16 |
| BR112013031685B1 (pt) | 2021-04-06 |
| LT2717914T (lt) | 2020-03-25 |
| CA2838289A1 (en) | 2013-03-14 |
| NZ619707A (en) | 2015-01-30 |
| HUE047737T2 (hu) | 2020-05-28 |
| HRP20192276T1 (hr) | 2020-05-15 |
| RS60051B1 (sr) | 2020-04-30 |
| CN103945865A (zh) | 2014-07-23 |
| CA2838289C (en) | 2019-09-10 |
| US9814773B2 (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2761340T3 (es) | Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas | |
| CN101060831B (zh) | 可方便植入的缓释药物组合物 | |
| EP2142189B1 (en) | Methods and compositions for intraocular administration to treat ocular conditions | |
| Iyer et al. | Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration | |
| JP2007535536A (ja) | 高分子含有持続放出眼内インプラントおよび関連方法 | |
| JP6980671B2 (ja) | 眼科用組成物 | |
| US20160130321A1 (en) | Use of a vegf antagonist in treating macular edema | |
| KR20150058510A (ko) | 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템 | |
| US20200375889A1 (en) | Bioerodible polyester polymer implants and related methods of use | |
| Ugurlu et al. | Transscleral delivery of bevacizumab-loaded chitosan nanoparticles | |
| ES2616296T3 (es) | Micropartículas de liberación controlada | |
| ES3006986T3 (en) | Biodegradable compositions and implants | |
| US20220054407A1 (en) | Ocular compositions | |
| NZ619707B2 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| HK1196081A (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| HK1196081B (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| Kapoor et al. | Long-Acting Intraocular Delivery Approaches for Biological Therapy of Age-Related Macular Degeneration | |
| Kimura et al. | Biodegradable systems |